HDAC6-IN-44
HDAC6-IN-44 (compound H10) is a selective HDAC6 inhibitor with an IC50 value of 8.97 nM. HDAC6-IN-44 can inhibit the idiopathic pulmonary fibrosis (IPF) phenotype and exhibits antifibrotic activity. Additionally, HDAC6-IN-44 reduces fibrogenesis in a bleomycin-induced pulmonary fibrosis mouse model and demonstrates good metabolic stability. HDAC6-IN-44 holds promise for research in the field of idiopathic pulmonary fibrosis.
For research use only. We do not sell to patients.
- Formula: C20H21N3O3
- Molecular Weight:351.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HDAC6 8.97 nM (IC50) |
HDAC1 878 nM (IC50) |
HDAC2 3144 nM (IC50) |
HDAC4 847 nM (IC50) |
HDAC7 894 nM (IC50) |
HDAC10 1319 nM (IC50) |
HDAC11 >5000 nM (IC50) |
In Vitro
HDAC6-IN-44 (compound H10) (2.5-10 μM, 1-300 μM, 48 h) inhibits TGF-β-induced proliferation of HELF cells, cell proliferation and their HDAC6 activity in a dose-dependent manner without causing significant cytotoxic effects[1].
HDAC6-IN-44 interferes with the TGF-β1-related fibrosis process by acting on HDAC6-related signaling pathways[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HELF cells
-
Concentration:2.5-10 μM (cell proliferation test), 1-300 μM (survival toxicity test)
-
Incubation Time:48 h
-
Result:Inhibited TGF-β-induced HELF cell proliferation without significantly inhibiting cell survival at a maximum concentration of approximately 10 μM.
-
Cell Line:HELF cells
-
Concentration:2.5-10 μM
-
Incubation Time:48 h
-
Result:Exhibited dose-dependent increase in acetylated α-tubulin expression and has no effect on histone H3 acetylation, while attenuating the elevated expression of all marker proteins induced by TGF-β1.
In Vivo
HDAC6-IN-44 (0.1 mL/10g, i.p., daily for 3 weeks) can inhibit the progression of pulmonary fibrosis in a dose-dependent manner in a mouse model of pulmonary fibrosis[1].
Cell Viability Assay[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Bleomycin-induced pulmonary fibrosis mouse model[1]
-
Dosage:0.1 mL/10g
-
Administration:Intraperitoneal injection (i.p.) , daily for 3 weeks
-
Result:Caused the blue collagen fiber deposition to be spot-like, with the surrounding alveolar cavity slightly collapsed and the alveolar wall thickened, but the collagen fiber deposition was significantly less than that in the model group. Additionally, HDAC6-IN-44 could dose-dependently inhibit the expression of α-SMA and p-Smad2/3 in BLM-induced pulmonary fibrosis in mice.
Chemical Information
-
Molecular Weight 351.40
-
Formula C20H21N3O3
-
SMILES
O=C(NO)C1=CC=C(CN2C([C@@](CCC3)([H])N3CC4=CC=CC=C42)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)